Talquetamab in heavily pretreated patients with multiple myeloma, including BCMA-refractory

Abstract: Talquetamab is a G protein–coupled receptor class C group 5 member D–targeting bispecific T-cell engager approved for patients with relapsed multiple myeloma based on the MonumenTAL-1 trial. In this retrospective study of 68 patients, we evaluated safety and efficacy of talquetamab in a re...

Descripció completa

Dades bibliogràfiques

Autors principals:	Andrew J. Vegel, Bradley T. Loeffler, Jonathan Lochner, Reed Friend, Alma Habib, Marshall McKenna, Jordan Snyder, Kimberly Green, Rachel DiLeo, Gina Patrus, Prerna Mewawalla, Muhammad Umair Mushtaq, Christopher Strouse, Yun Kyoung Ryu Tiger, Nausheen Ahmed, Abdullah M. Khan, Hamza Hashmi, Barry Paul, Shebli Atrash, Al-Ola Abdallah, Hira Shaikh
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2025-06-01
Col·lecció:	Blood Immunology & Cellular Therapy
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S3050597625000016
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!